Lots in the papers this morning about the US company, Geron, halting its stem cell study on spinal cord injury.
I thought I would share this coverage from the Washington Post.
Geron’s decision highlights a lot of interesting issues around science funding..
..the long-term nature of science
…the difficulties for the private sector in keeping shareholders on side for such a long-term venture
…..the importance therefore of public funding in sustaining this sort of work
……and, as the Post says, the ‘fledgling’ nature of the stem cell ‘market’ if I can put it like that.